Cargando…

Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions

Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Guoming, Jin, Libo, Ying, Qinsi, Chen, Haojie, Thembinkosi, Murinda Charmaine, Yang, Chunguang, Zhao, Jinlong, Ji, Hao, Lin, Sue, Peng, Renyi, Zhang, Maolan, Sun, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586057/
https://www.ncbi.nlm.nih.gov/pubmed/33116895
http://dx.doi.org/10.2147/CMAR.S265828
_version_ 1783599919705096192
author Zeng, Guoming
Jin, Libo
Ying, Qinsi
Chen, Haojie
Thembinkosi, Murinda Charmaine
Yang, Chunguang
Zhao, Jinlong
Ji, Hao
Lin, Sue
Peng, Renyi
Zhang, Maolan
Sun, Da
author_facet Zeng, Guoming
Jin, Libo
Ying, Qinsi
Chen, Haojie
Thembinkosi, Murinda Charmaine
Yang, Chunguang
Zhao, Jinlong
Ji, Hao
Lin, Sue
Peng, Renyi
Zhang, Maolan
Sun, Da
author_sort Zeng, Guoming
collection PubMed
description Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer.
format Online
Article
Text
id pubmed-7586057
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75860572020-10-27 Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions Zeng, Guoming Jin, Libo Ying, Qinsi Chen, Haojie Thembinkosi, Murinda Charmaine Yang, Chunguang Zhao, Jinlong Ji, Hao Lin, Sue Peng, Renyi Zhang, Maolan Sun, Da Cancer Manag Res Review Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer. Dove 2020-10-21 /pmc/articles/PMC7586057/ /pubmed/33116895 http://dx.doi.org/10.2147/CMAR.S265828 Text en © 2020 Zeng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zeng, Guoming
Jin, Libo
Ying, Qinsi
Chen, Haojie
Thembinkosi, Murinda Charmaine
Yang, Chunguang
Zhao, Jinlong
Ji, Hao
Lin, Sue
Peng, Renyi
Zhang, Maolan
Sun, Da
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title_full Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title_fullStr Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title_full_unstemmed Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title_short Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
title_sort regulatory t cells in cancer immunotherapy: basic research outcomes and clinical directions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586057/
https://www.ncbi.nlm.nih.gov/pubmed/33116895
http://dx.doi.org/10.2147/CMAR.S265828
work_keys_str_mv AT zengguoming regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT jinlibo regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT yingqinsi regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT chenhaojie regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT thembinkosimurindacharmaine regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT yangchunguang regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT zhaojinlong regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT jihao regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT linsue regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT pengrenyi regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT zhangmaolan regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections
AT sunda regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections